Form 4 for EVMN Evommune, Inc.
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-17 · accession 0002094941-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-02-18 | 2026-02-17 | EVMN | Verduyn-van Weegen Felice Isabel | Dir, 10% | A - Grant | $27.88 | +358.7K | 5.29M | +7% | +$10.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | A | A | 358,680 | $27.88 | 5,288,313 | I By LSP 7 Cooperatief U.A. | — | — | (F1) These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. |